Clinical Trial Update: Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adjuvant befotertinib in stage IB-IIIB non-small cell lung cancer with EGFR sensitive mutations is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Status: RECRUITING